1,633 Spam-Free Article(s) Found
Sort:
Date
Filter:
All
Symbol Name Last Close Mkt Cap DailyStocks'
Rating
Our DailyStocks’ Rating System is a proprietary algorithm that combines the vote of the investor community and legendary trader Richard Dennis’ Turtle Trader System and the System Rules of the Turtle Traders Each day, we generate Buy, Sell, Uptrend or Downtrend signals for 3000 Stocks in the U.S. Markets.
Vote Now!
Thursday’s Close
AMGN Amgen Inc. $200.81 $129.98B Buy
Article Searches
AbbVie Suffers Market Loss For Humira In Europe, But The U.S. Is A Different Story https://seekingalpha.com/article/4240000-abbvie-suffers-market-loss-humira-europe-u-s-different-story?source=feed_sector_healthcare Feb 11, 2019 - AbbVie missed its Q4 earnings expectations, but it does have many other products to help it get back on track in the coming quarters.The big loss for the quarter was due to international sales of Humi
Amgen: One Of The Best Dividend Growth Stocks In The Market Has Gone On Sale https://seekingalpha.com/article/4239798-amgen-one-best-dividend-growth-stocks-market-gone-sale?source=feed_sector_healthcare Feb 11, 2019 - Amgen's shares yield more than 3% and offer some of the best dividend growth metrics in the market.Over the long term, this stock's performance has crushed the broader market's.Growth appears to be sl
10 Dividend Growth Stocks For February 2019 https://seekingalpha.com/article/4238509-10-dividend-growth-stocks-february-2019?source=feed_all_articles Feb 07, 2019 - I rank a selection of the CCC stocks and present the top 10 for consideration.Given increased market volatility, I'm focusing on defensive sectors.This month I'm ranking CCC stocks in the Health Care
Roche Submits sBLA to FDA for Label Expansion of Kadcyla http://www.zacks.com/stock/news/352051/roche-submits-sbla-to-fda-for-label-expansion-of-kadcyla?cid=CS-ZC-FT-352051 Feb 05, 2019 - Roche (RHHBY) submits sBLA for Kadcyla to the FDA for adjuvant treatment of patients with HER2-positive early breast cancer with residual disease after neoadjuvant treatment.
Teva Gains Positive CHMP Opinion for Migraine Drug Ajovy http://www.zacks.com/stock/news/351848/teva-gains-positive-chmp-opinion-for-migraine-drug-ajovy?cid=CS-ZC-FT-351848 Feb 04, 2019 - Teva (TEVA) receives positive opinion from the Committee for Medicinal Products for Human Use (CHMP), advocating a marketing approval for its new migraine medicine, Ajovy.
Pfizer's (PFE) New Lung Cancer Drug Vizimpro Gets CHMP Nod http://www.zacks.com/stock/news/351766/pfizers-pfe-new-lung-cancer-drug-vizimpro-gets-chmp-nod?cid=CS-ZC-FT-351766 Feb 04, 2019 - Pfizer's (PFE) new lung cancer medicine, Vizimpro (dacomitinib) gets recommendation from CHMP of the EMA.
Roche (RHHBY) 2018 Sales Up on Solid New Drugs Performance http://www.zacks.com/stock/news/351665/roche-rhhby-2018-sales-up-on-solid-new-drugs-performance?cid=CS-ZC-FT-351665 Feb 01, 2019 - Roche's (RHHBY) performance in 2018 is driven by solid strength in new drugs, which more than offset competition from biosimilars.
Amgen on hunt for acquisitions to drive growth https://seekingalpha.com/news/3427621-amgen-hunt-acquisitions-drive-growth?source=feed_news_all Jan 30, 2019 - During its Q4 earnings call, Amgen (AMGN -5.2%) chief Bob Bradway said his company is maintaining its attention on potential acquisitions, large and small, that represent reasonable valuations for exp
Your first trade for Wednesday, January 30 https://www.cnbc.com/2019/01/30/your-first-trade-for-wednesday-january-30.html Jan 30, 2019 - The "Fast Money" traders share their first moves for the market open.
Amgen (AMGN) Q4 Earnings Beat Estimates, 2019 Guidance Tepid http://www.zacks.com/stock/news/350621/amgen-amgn-q4-earnings-beat-estimates-2019-guidance-tepid?cid=CS-ZC-FT-350621 Jan 30, 2019 - Amgen (AMGN) beats estimates for both earnings and sales in Q4. Its forecast for 2019 disappoints investors Stock dips 2.4% in after-hours trading.

Pages: 123456789...164

<<<Page 4>